Uncategorized
Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

Sirona Biochem Announces Close of Oversubscribed Private Placement

 

 

 

 

 

Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (Xetra: ZSB) announced today that it has closed an oversubscribed, non-brokered private placement for gross proceeds of $1,783,500. The private placement consists of 17,835,000 units, at a price of $0.10 per Unit.  Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant is exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.16 per share.

 

All securities issued under the placement are subject to a statutory hold period expiring on June 27, 2019.

 

The Company compensated finders by way of cash fees of $62,136 and 621,360 warrants.

 

The financing consisted of participation by PRO-group member Shaun Chin of PI Financial, for 500,000 units, as well as two insiders. Dr. Howard Verrico, CEO, has participated with the purchase of 960,000 Units and Christopher Hopton, CFO, has participated with a purchase of 350,000 Units.

 

Net proceeds of the placement will be used for general working capital while the company continues its efforts toward licensing and commercialization of various pipeline products.

 

The Company also announced that it has granted incentive stock options under its Stock Option Plan to directors and officers of the Company for the purchase of up to 700,000 common shares at a price of $0.12 per share. Directors will receive 400,000 options at $0.12 with a 5 year expiry and Officers will receive 300,000 options at $0.12 with a 10 year expiry.

 

About Sirona Biochem Corp.

 

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

 

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants.

 

Posted February 27, 2019

Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

MORE or "UNCATEGORIZED"


Khiron Announces Closing of $28.75 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option

Khiron Life Sciences Corp. (TSX-V:KHRN) (OTCQB:KHRNF), a cannabis... READ MORE

May 28, 2019

Harborside Closes C$19.65 Million Financing

FLRish Inc. d/b/a/ Harborside, a California corporation which man... READ MORE

May 28, 2019

TerrAscend Announces Closing on $69 Million Non-Brokered Private Placement

TerrAscend Corp. (CSE:TER) (OTCQX:TRSSF) has completed its previo... READ MORE

May 28, 2019

Construction of a hydroelectric generating station for the energy transition in the Inukjuak off-grid system

Innergex Renewable Energy Inc. (TSX: INE) the Pituvik Landholding... READ MORE

May 27, 2019

C21 Investments completes acquisition of Swell Companies

C21 Investments Inc. (CSE: CXXI) (OTC: CXXIF) today announced tha... READ MORE

May 27, 2019

Copyright 2025 The Venture Report